Third Circuit Creates Reverse Payments Split among the Circuits

by Proskauer Rose LLP
Contact

Rejecting the test established by three separate courts of appeal, the Third Circuit's recent decision in In re K-Dur Antitrust Litigation has created a circuit split regarding the legality of, and application of antitrust law to, "pay-for-delay" settlements to patent lawsuits. See 2012 WL 2877662 (3rd Cir. 2012). The case is significant because it represents a reversal of fortune for pharmaceutical companies that had sought to settle patent litigation, and had – to date – largely escaped antitrust liability. The newly-created split, however, is likely to garner attention from the Supreme Court.

"Pay-for-delay" or "reverse payments" suits arise when a branded pharmaceutical manufacturer and the generic manufacturer settle patent litigation. Many such settlements include a payment by the branded firm to the generic manufacturer and an agreement by the generic manufacturer to begin marketing before the expiration of the nominal term of the patent (but at a point later than when, plaintiffs have argued, the generic would have entered). The payment works "in reverse" because the money flows from the patent owner to the potential infringer, not in the opposite direction, as is the case in most patent settlements. The Federal Trade Commission, and plaintiffs like those in the K-Dur case (e.g., retail pharmacies), have long argued that such terms should not be viewed as a "settlement" of litigation, but as a payoff to prevent or delay competition.

Courts addressing this issue initially expressed skepticism of these settlements, but of late – at least until K-Dur – have upheld them. The general rule developed by courts reviewing reverse payment suits in recent years has been to examine whether the term requiring the generic to forego market entry exceeds the "scope of the patent." Under this test, courts examine whether the settlement blocks entry beyond what the patent on its face could have prevented. In other words, because in the Patent Act Congress declared patent grants presumptively valid, a settlement within the Congressional grant does not create competitive effects beyond or in addition to the Congressional grant. Thus under this test there is no antitrust claim, even if the reverse payment was expressly designed to prevent generic entry (upon a finding of patent invalidity) and the competition that would ensue.

Notably, the "tipping point" in this area was the Eleventh Circuit's decision in a predecessor case to K-Dur, involving the same drug and manufacturers. The drug, K-Dur, is a branded drug produced by Schering Plough. After Schering settled patent litigation brought by Upsher (the generic challenger), the FTC issued an order finding the reverse payment unlawful. Schering appealed, and the Eleventh Circuit held that the payment could be construed as a fee for a separately licensed drug and, in any event, that a settlement permitting entry before the patent expiration was a "reasonable implementation" of the protections afforded by patent law. Schering Plough Corp. v. FTC, 402 F.3d 1056, 1072 (11th Cir. 2005). The Eleventh Circuit recently reaffirmed its rule in FTC. v. Watson Chemicals, No. 10-12729 (11th Cir. April 25, 2012). Following Schering, the Second Circuit in In re Tamoxifen, 466 F.3d 187 (2d Cir. 2006), and the Federal Circuit, in In re Ciprofloxacin, 544 F.3d 1323 (Fed. Cir. 2008), reached similar conclusions.

After Schering, generic and innovator companies have entered into a number of additional "reverse payment" settlements. The FTC has continued to rally against these types of settlements, seeking legislative solutions and launching investigations. But its hands have largely been tied because any final order of the Commission could be appealed to the circuit of the pharmaceutical company's choosing. This meant that defendants would always choose the Eleventh Circuit, effectively preventing the FTC from creating a circuit split.

The K-Dur case, however, changes the landscape. The plaintiffs there were private parties, with the right to sue in their chosen forum. Thus, though the Eleventh Circuit upheld the same settlement in the FTC challenge, the private plaintiffs were able to try their luck in the Third Circuit, a forum generally viewed as more antitrust plaintiff-friendly. Last week, they succeeded.

In K-Dur, the Third Circuit not only held that reverse payment settlements are subject to antitrust challenge, but are presumptively unlawful. In the Third Circuit's view, the "scope of the patent test" improperly "restricts the application of antitrust law and is contrary to … a long line of Supreme Court precedent on patent litigation and competition." In the court's view, that test  may indeed foster settlements, but at the cost of permitting the continuation of questionable patents (which might otherwise be found invalid or not infringed) and, more importantly, the continuation of monopoly products in the marketplace.

In place of the "scope of the patent" test, the Third Circuit instructed courts in its circuit to apply a "quick look rule of reason analysis based on the economic realities of the reverse payment settlement." In particular, courts should now treat the reverse payment itself as "prima facie evidence of an unreasonable restrain of trade." That presumption may be rebutted if defendants can show the payment "was for a purpose other than delayed entry" or "offers some pro-competitive benefit." In practice, given that the court agreed that it was unnecessary to consider the merits of the underlying patent suit, it will be difficult for a defendant to overcome the presumption unless it receives significant value for the generic in addition to delayed entry, like a license to valuable intellectually property belonging to the generic, a distribution arrangement, etc.

What appears to be a plaintiff-friendly rule in the Third Circuit may be short-lived, however. Back when the FTC lost Schering in the Eleventh Circuit, it sought certiorari from the Supreme Court. In a rare case of division among federal departments, the Solicitor General filed a brief opposing the FTC's petition, primarily because there was no split among the circuits. That split, once absent, is now stark. As such there is a significant chance that the petition of Schering Plough (the company is now owned by Merck) will be granted.

Written by:

Proskauer Rose LLP
Contact
more
less

Proskauer Rose LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.